Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Clinical trial NCT00569127 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT00569127
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Colorectal Neuroendocrine Tumor G1 Gastric Neuroendocrine Tumor G1 Neuroendocrine Neoplasm Neuroendocrine Tumor Neuroendocrine Tumor G2

Start date: 2007-12-01
Primary completion: 2015-01-01
Enrollment: 427

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.